EverSource Wealth Advisors LLC Has $222,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

EverSource Wealth Advisors LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,399 shares of the biopharmaceutical company’s stock after acquiring an additional 167 shares during the period. EverSource Wealth Advisors LLC’s holdings in Gilead Sciences were worth $222,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in GILD. HighTower Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.7% in the fourth quarter. HighTower Advisors LLC now owns 1,793,699 shares of the biopharmaceutical company’s stock valued at $165,684,000 after purchasing an additional 12,746 shares in the last quarter. Natural Investments LLC bought a new position in Gilead Sciences during the 4th quarter valued at $460,000. Avantax Planning Partners Inc. boosted its holdings in Gilead Sciences by 9.6% during the 4th quarter. Avantax Planning Partners Inc. now owns 3,659 shares of the biopharmaceutical company’s stock worth $338,000 after acquiring an additional 322 shares during the last quarter. Citizens Financial Group Inc. RI grew its stake in shares of Gilead Sciences by 58.6% in the 4th quarter. Citizens Financial Group Inc. RI now owns 10,027 shares of the biopharmaceutical company’s stock worth $926,000 after acquiring an additional 3,706 shares in the last quarter. Finally, Pzena Investment Management LLC raised its holdings in shares of Gilead Sciences by 22.8% in the fourth quarter. Pzena Investment Management LLC now owns 3,223 shares of the biopharmaceutical company’s stock valued at $298,000 after purchasing an additional 599 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $111.44 on Monday. The firm has a 50 day simple moving average of $101.82 and a two-hundred day simple moving average of $92.92. The stock has a market cap of $138.78 billion, a PE ratio of 301.19, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on GILD shares. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Oppenheimer upped their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Bank of America raised their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 302,785 shares of company stock worth $30,503,250 in the last quarter. 0.16% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.